Kamada Ltd. Ordinary Shares (KMDA)
Stock · NASDAQ · Health Care
$7.74as of 10/16/2026
Price chart
Active signals
Resistance level
$8.19
Industry
Biotechnology: Pharmaceutical Preparations
KMDA Signal Track Record
How signals performed across all stocks →What KMDA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | +1.7% | 65% | September 1, 2026 |
| Bollinger Band Breakout | 26 | -2.2% | 35% | September 18, 2026 |
| 200-Day Moving Average TouchActive now | 23 | +0.7% | 57% | October 7, 2026 |
| Bollinger Band Breakdown | 19 | +5.1% | 74% | July 16, 2026 |
| Any 20-session window (baseline) | +0.5% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KMDA
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for p…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 462
- Website
- www.kamada.com/
Fundamentals
- 1-day range
- $7.66$7.84
- Market cap
- $411.88M
- P/E (trailing)
- 20.30
- P/E (forward)
- 13.58
- EPS (trailing)
- $0.38
- Dividend yield
- 3.53%
- Beta
- 0.92
- Avg. volume
- 122.1K
- Ex-dividend date
- August 27, 2026
- Dividend pay date
- September 17, 2026
52-week range
$6.55$9.35
Next earnings: November 9, 2026 · EPS estimate $0.13confirmed
Forecasts
4 analyst ratings
Buy 89%
Hold 11%
Sell 0%
1-year price forecast
High
$15
+93.8%
Median
$14
+80.9%
Low
$11
+42.1%
Kamada Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- KMDAKamada Ltd. Ordinary Shares$7.76▼ 0.89%Market cap $411.88MP/E 20.30$6.55$9.35
- PBYIPuma Biotechnology Inc Common Stock$9.83▼ 6.56%Market cap $413.30MP/E 20.62$4.58$10.5
- ASMBAssembly Biosciences Inc. Common Stock$20.09▼ 2.33%Market cap $420.36MP/E 333.50$19.98$39.71
- AVIRAtea Pharmaceuticals Inc. Common Stock$4.32▼ 4.64%Market cap $399.34MP/E —$2.87$6.45
- ABEOAbeona Therapeutics Inc. Common Stock$4.43▼ 4.73%Market cap $393.27MP/E 5.50$4$7.65
- ENTAEnanta Pharmaceuticals Inc. Common Stock$11.1▼ 3.23%Market cap $387.91MP/E —$10.2$17.15
- LRMRLarimar Therapeutics Inc. Common Stock$1.99▼ 0.25%Market cap $436.31MP/E —$2.06$6.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KMDA Kamada Ltd. Ordinary Shares | $411.88M | 20.30 | $7.76 | ▼ 0.89% | $6.55$9.35 |
| PBYI Puma Biotechnology Inc Common Stock | $413.30M | 20.62 | $9.83 | ▼ 6.56% | $4.58$10.5 |
| ASMB Assembly Biosciences Inc. Common Stock | $420.36M | 333.50 | $20.09 | ▼ 2.33% | $19.98$39.71 |
| AVIR Atea Pharmaceuticals Inc. Common Stock | $399.34M | — | $4.32 | ▼ 4.64% | $2.87$6.45 |
| ABEO Abeona Therapeutics Inc. Common Stock | $393.27M | 5.50 | $4.43 | ▼ 4.73% | $4$7.65 |
| ENTA Enanta Pharmaceuticals Inc. Common Stock | $387.91M | — | $11.1 | ▼ 3.23% | $10.2$17.15 |
| LRMR Larimar Therapeutics Inc. Common Stock | $436.31M | — | $1.99 | ▼ 0.25% | $2.06$6.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Kamada Expands Biosimilar Portfolio With Commercial Launch Of Two Additional New Products In Israel, Adding To Existing Portfolio Of Two Productsbenzinga · 10/6/2026
- Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in IsraelYahoo · 10/6/2026
- Kamada Expands Biosimilar Portfolio With Commercial Launch Of Two Additional New Products In Israel, Adding To Existing Portfolio Of Two ProductsBenzinga · 10/6/2026
- Lilach Asher Topilsky At Kamada Secures Company Stock Options: $166K AcquiredBenzinga · 9/30/2026
- Witness A Substantial Acquisition As Uri Botzer Acquires $138K In Kamada Stock OptionsBenzinga · 9/30/2026
- Significant Move: Ishay Davidi Invests $152K In Kamada Stock OptionsBenzinga · 9/30/2026
- Significant Move: Ishay Davidi Invests $162K In Kamada Stock OptionsBenzinga · 9/29/2026
- Strategic Investment: Uri Botzer Boosts Portfolio With $148K In Kamada Stock OptionsBenzinga · 9/29/2026
- Director At Kamada Acquires Company Stock Options Worth $162KBenzinga · 9/29/2026
Insider Activity
Insider Actions →Acquired
52.5K
Disposed
209.0K
- Brenner Yael · September 14, 2026 · Option Exercise5.5K @ $5.93
- Brenner Yael · September 14, 2026 · Option Exercise5.0K @ $5.93
- Brenner Yael · September 14, 2026 · Tax Withholding1.5K @ $8.35
- Brenner Yael · September 14, 2026 · Tax Withholding1.8K @ $8.36
- Brenner Yael · September 14, 2026 · Tax Withholding1.4K @ $8.36
- Livneh Nir · September 14, 2026 · Option Exercise10.0K @ $5.37
- Livneh Nir · September 14, 2026 · Tax Withholding3.5K @ $8.35
- Tsur David · September 14, 2026 · Sale22.8K @ $8.18
- Brenner Yael · September 14, 2026 · Option Exercise6.5K @ $5.93
- Tsur David · September 9, 2026 · Sale175 @ $8.26
- Tsur David · September 8, 2026 · Sale162.8K @ $8.26
- Tsur David · September 7, 2026 · Sale14.2K @ $8.28
- Brenner Yael · September 2, 2026 · Option Exercise3.0K @ $5.94
- Brenner Yael · September 2, 2026 · Tax Withholding865 @ $8.37
- Tsur David · September 2, 2026 · Option Exercise22.5K @ $5.94
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Multiple Insiders Acquire Kamada Stock Options
Recent filings show several Kamada insiders purchased stock options, with amounts ranging from $59,000 to $1.8 million. The purchases were made by individuals including Amir London, David Tsur, Eran Nir and others. Such activity may reflect confidence in the company's prospects. The stock is currently trading near the upper end of its 52‑week range.
Multiple Insiders Acquire Kamada Stock Options. Recent filings show several Kamada insiders purchased stock options, with amounts ranging from $59,000 to $1.8 million. The purchases were made by individuals including Amir London, David Tsur, Eran Nir and others. Such activity may reflect confidence in the company's prospects. The stock is currently trading near the upper end of its 52‑week range.